Poniard Pharmaceuticals, Inc. (PARD) - OTCPK - No Info
  • Feb. 3, 2010, 2:16 PM

    Shares of Poniard Pharmaceuticals (PARD) -8.8% after the firm said it's replacing its CEO and cutting its work force by 57%. Moves come after disappointing results last week from a Phase II trial of its cancer drug picoplatin. Shares are down 76% over the past three months.

    | Feb. 3, 2010, 2:16 PM
  • May 28, 2009, 9:02 AM

    Premarket gainers: EXEL +26%. PPHM +23%. ANPI +23%. PARD +14%. SANM +6%. BIG +6%. DRYS +5%. XOMA +5%. TSL +5%. FRO +5%. RYAAY +5%. CIT +4%. ABK +4%. FIG +4%. SOLF +4%.
    Losers: BCSI -9%. TEX -9%. LEAP -6%. GM -6%. TWO -5%. SBLK -4%.

    | May 28, 2009, 9:02 AM
Company Description
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products. For additional information please visit http://www.poniard.com.
Sector: Healthcare
Industry: Biotechnology
Country: United States